{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:54:24Z","timestamp":1770281664110,"version":"3.49.0"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,11,10]],"date-time":"2004-11-10T00:00:00Z","timestamp":1100044800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Optimal diagnosis and timely treatment of atypical mycobacteriosis, and especially <jats:italic>Mycobacterium kansasii<\/jats:italic> disease, remain a serious challenge for clinicians engaged in the management of the immunocompromised host.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>From more than 2700 hospitalizations (over 1800 patients) attributable to HIV\u2010associated disorders over an 11\u2010year period, 12 patients were found to have a confirmed <jats:italic>M. kansasii<\/jats:italic> infection. This reflects the recent reduction in the frequency of this HIV\u2010related complication, which virtually disappeared after the introduction of potent antiretroviral combinations in 1996. In the early 1990s, the lack of effective antiretroviral regimens made frequent the association with AIDS, a mean CD4 lymphocyte count of nearly 20 cells\/\u03bcL, and an extremely variable chest X\u2010ray features. The recent detection of a further case was attributable to late recognition of very advanced HIV disease, complicated by multiple opportunistic disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p> <jats:italic>Mycobacterium kansasii<\/jats:italic> respiratory or disseminated infection continues to occur, and poses diagnostic problems in terms of late or missed identification as a result of slow culture and frequently concurrent opportunistic disease. Serious therapeutic difficulties also arise from the unpredictable <jats:italic>in vitro<\/jats:italic> antimicrobial susceptibility profile of these organisms, and from the need to start an effective combination therapy that does not interfere with other medications as soon as possible.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2004.00249.x","type":"journal-article","created":{"date-parts":[[2004,11,15]],"date-time":"2004-11-15T18:43:47Z","timestamp":1100544227000},"page":"431-436","source":"Crossref","is-referenced-by-count":6,"title":["Epidemiological, clinical and therapeutic features of AIDS\u2010related <i>Mycobacterium kansasii<\/i> infection during the HIV pandemic: an 11\u2010year follow\u2010up study"],"prefix":"10.1111","volume":"5","author":[{"given":"R","family":"Manfredi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Nanetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Calza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,11,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960100494"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(98)92014-X"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.36.298"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/313519"},{"key":"e_1_2_5_7_2","first-page":"698","article-title":"Incidence and clinical implications of isolation of Mycobacterium kansasii","volume":"129","author":"Block KC","year":"1998","journal-title":"results of a 5-year, population-based study"},{"key":"e_1_2_5_8_2","first-page":"68","article-title":"Mycobacterium kansasii infection in a Paris suburb","volume":"3","author":"Lortholary O","year":"1999","journal-title":"comparison of disease presentation and outcome according to human immunodeficiency virus status"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.1.9808052"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-001-0061-x"},{"key":"e_1_2_5_11_2","unstructured":"National Centres for Clinical and Laboratory Standards (NCCLS).Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement Vol. 22. Philadelphia PA USA National Centres for Clinical and Laboratory Standards 2002."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/317441"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01089-6"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050307"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050351"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462991914744"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.1997"},{"key":"e_1_2_5_18_2","first-page":"1359","article-title":"Mechanisms of pyrazinamide resistance in mycobacteria","volume":"145","author":"Raynaud C","year":"1999","journal-title":"importance of lack of uptake in addition to lack of pyrazinamidase activity"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.1.39-42.2000"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.4.417"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.3.537"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00013-3"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2004.00249.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2004.00249.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:50:23Z","timestamp":1696909823000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2004.00249.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1111\/j.1468-1293.2004.00249.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2004.00249.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}